Literature DB >> 8146956

Pharmacokinetics of benzydamine in dairy cows following intravenous or intramuscular administration.

P Anfossi1, J Malvisi, N Catraro, M Bolognini, L Tomasi, G L Stracciari.   

Abstract

Five lactating cows were given benzydamine hydrochloride by rapid intravenous (0.45 mg/kg) and by intramuscular (0.45 and 1.2 mg/kg) injection in a crossover design. The bioavailability, pharmacokinetic parameters and excretion in milk of benzydamine were evaluated. After intravenous administration, the disposition kinetics of benzydamine was best described using a two-compartment open model. Drug disposition and elimination were fast (t1/2 alpha: 11.13 +/- 3.76 min; t1/2 beta: 71.98 +/- 24.75 min; MRT 70.69 +/- 11.97 min). Benzydamine was widely distributed in the body fluids and tissues (Vd(area): 3.549 +/- 1.301 L/kg) and characterized by a high value for body clearance (33.00 +/- 5.54 ml/kg per min). After intramuscular administration the serum concentration-time curves fitted a one-compartment open model. Following a dose of 0.45 mg/kg, the Cmax value was 38.13 +/- 4.2 ng/ml at a tmax of 67.13 +/- 4.00 min; MAT and MRT were 207.33 +/- 22.64 min and 278.01 +/- 12.22 min, respectively. Benzydamine bioavailability was very high (92.07% +/- 7.08%). An increased intramuscular dose (1.2 mg/kg) resulted in longer serum persistence (MRT 420.34 +/- 86.39 min) of the drug, which was also detectable in milk samples collected from both the first and second milking after treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8146956     DOI: 10.1007/bf01839222

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  11 in total

1.  Metabolism of benzydamine hydrochloride: species differences and the identification of unconjugated metabolites in rabbit urine.

Authors:  S Kataoka; K Taira; T Ariyoshi; E Takabatake
Journal:  Chem Pharm Bull (Tokyo)       Date:  1973-02       Impact factor: 1.645

2.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

3.  Additional pharmacological studies on benzydamine.

Authors:  B Silvestrini; A Garau; C Pozzatti; V Cioli; B Catanese
Journal:  Arch Int Pharmacodyn Ther       Date:  1966-09

4.  Studies on the absorption and elimination of benzydamine in the mouse, rat, dog, and man.

Authors:  B Catanese; A Grasso; B Silverstrini
Journal:  Arzneimittelforschung       Date:  1966-10

Review 5.  Review of pharmacological data on benzydamine.

Authors:  V Cioli; C Corradino; P Scorza Barcellona
Journal:  Int J Tissue React       Date:  1985

6.  Aspects of the mechanisms of action of benzydamine.

Authors:  G Segre; S Hammarström
Journal:  Int J Tissue React       Date:  1985

7.  Pharmacokinetics of benzydamine.

Authors:  L F Chasseaud; B Catanese
Journal:  Int J Tissue React       Date:  1985

8.  Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects.

Authors:  G A Baldock; R R Brodie; L F Chasseaud; T Taylor; L M Walmsley; B Catanese
Journal:  Biopharm Drug Dispos       Date:  1991-10       Impact factor: 1.627

9.  A method for the determination of 1-benzyl-3[3'-(dimethylamino) propoxy]-1H-indazole (benzydamine) in rat tissues.

Authors:  E Giacalone; L Valzelli
Journal:  Med Pharmacol Exp Int J Exp Med       Date:  1966

10.  The pharmacokinetics of diclofenac sodium following intravenous and oral administration.

Authors:  J V Willis; M J Kendall; R M Flinn; D P Thornhill; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.